Who are intraperitoneal nebulisation of magnesium sulphate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intraperitoneal-nebulisation-of-magnesium-sulphate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

intraperitoneal nebulisation of magnesium sulphate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

intraperitoneal nebulisation of magnesium sulphate (intraperitoneal nebulisation of magnesium sulphate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineral supplement / Anti-inflammatory agent. Area: Pain management / Perioperative care.

marketed Mineral supplement / Anti-inflammatory agent NMDA receptor (indirect antagonism); local anti-inflammatory pathways Pain management / Perioperative care Small molecule Live · refreshed every 30 min

Target snapshot

intraperitoneal nebulisation of magnesium sulphate (intraperitoneal nebulisation of magnesium sulphate) — B.P. Koirala Institute of Health Sciences. Magnesium sulphate delivered intraperitoneally reduces visceral pain and inflammation through local anti-inflammatory effects and modulation of nociceptive pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intraperitoneal nebulisation of magnesium sulphate TARGET	intraperitoneal nebulisation of magnesium sulphate	B.P. Koirala Institute of Health Sciences	marketed	Mineral supplement / Anti-inflammatory agent	NMDA receptor (indirect antagonism); local anti-inflammatory pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineral supplement / Anti-inflammatory agent class)

B.P. Koirala Institute of Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intraperitoneal nebulisation of magnesium sulphate — Competitive Intelligence Brief. https://druglandscape.com/ci/intraperitoneal-nebulisation-of-magnesium-sulphate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab